Avita Medical is counting the catalysts for FY22

Avita Medical is counting on a lot of macro factors to go right for the company's earnings projections to pan out. At this particular juncture, the medtech reported a full year net loss of US$26m. While it's far better than last year's figure, it's still not a stellar effort. In much better news, revenues from a contract between Avita (AVH) and the US department of health are starting to come in. CEO Dr Michael Perry tells ausbiz that next year will be a year to limit cash burn as the company tries to remain debt-free and without a capital raise.